Eighty patients undergoing total knee arthroplasty were randomized to receive either liposomal bupivacaine (n=40) or conventional bupivacaine (n=40) in adductor canal blocks. The primary outcome of interest was pain scores within 72 hours postoperatively. Secondary outcomes included opioid consumption and length of hospital stay. Outcomes were assessed over a period of 72 hours post-surgery. Overall, the results of the study revealed that patients in the liposomal bupivacaine group had significantly lower opioid consumption during the 72-hour period, but there were no significant differences in pain scores or hospital stay between the groups. The findings suggest that liposomal bupivacaine may help reduce opioid use without impacting pain control or hospital length of stay.